At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
In Brief
A Phase 2 clinical trial evaluating Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001 and Laboratory Biomarker Analysis for Cervical Adenocarcinoma and 3 related conditions. Completed, enrolled 54 participants across 24 sites.
Detailed Summary
This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
CountriesUnited States
CollaboratorsAdvaxis, Inc., National Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartMay 2011
Primary CompletionOct 2018
TodayJul 2026
First PostedDec 24, 2010
Enrollment StartMay 23, 2011
Primary CompletionOct 2, 2018
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 15.5 years ago
Interventions
Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001biological
Given IV
Laboratory Biomarker Analysisother
Correlative studies